en · de · es · fr · pt
methods-notes.peptides7501.com › News › Identity, Natural Role, And Forms — Quick Reference

Identity, Natural Role, And Forms — Quick Reference

By Editorial Desk · published 2025-09-22 · last reviewed 2025-11-02 · News

phosphocreatine comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-11-02. Numbers and descriptions here follow the published literature rather than marketing material.

Identity, Natural Role, and Forms

In animals, creatine is synthesized mainly in liver, kidney, and pancreas from arginine, glycine, and methionine. The first committed step transfers a guanidino group from arginine to glycine, forming guanidinoacetate. Subsequent methylation by S-adenosylmethionine yields creatine. Dietary sources include meat and fish; endogenous synthesis supplies part of the body pool. Most creatine is stored in skeletal muscle, where it is converted to phosphocreatine and participates in rapid regeneration of adenosine triphosphate during short, intense activity.

Commercial creatine products appear in several forms, including monohydrate, hydrochloride, citrate, nitrate, and ethyl ester. Creatine monohydrate is the most studied form and serves as a reference material in comparative research. Different forms vary in solubility, pH, and water content, but they share creatine as the active moiety after dissolution. Claims that one form is uniformly superior remain debated, and study designs often differ in population, exercise protocol, and outcome measures. Purity and hydration state are central to interpreting product labels.

Creatine monohydrate is the hydrated form of creatine, a nitrogen-containing organic acid involved in cellular energy transfer. Its molecular formula is C4H11N3O3, and it consists of creatine plus one water molecule in the crystal lattice. The anhydrous base, creatine, has the formula C4H9N3O2. The compound appears as a white, odorless, crystalline powder and is classified as a guanidine derivative. It is distinct from creatinine, a breakdown product measured in clinical chemistry.

Background and Chemical Identity

In the body, creatine is obtained from dietary meat and fish and is also synthesized from arginine, glycine, and methionine. Muscle stores creatine and phosphocreatine, which participate in the rapid regeneration of adenosine triphosphate during short, intense activity. The monohydrate form is used in research because it is chemically defined, stable as a dry solid, and relatively inexpensive to produce. Questions remain about whether other creatine forms offer meaningful advantages in absorption or tissue retention, and findings vary across studies and populations.

Creatine monohydrate is a crystalline compound formed from creatine and one molecule of water. Creatine itself is a nitrogen-containing organic acid that occurs in vertebrate muscle and other tissues. The monohydrate designation refers to the water included in the crystal lattice, not to water added during manufacturing. Its chemical formula is commonly written as C4H9N3O2·H2O. The solid is typically a white, odorless powder with low solubility in water at room temperature. It is one of several creatine forms described in scientific and commercial literature.

The compound was identified in the nineteenth century after chemists isolated a nitrogenous substance from meat extracts. Later work established its role in muscle energy metabolism and its conversion to phosphocreatine. Chemical synthesis of creatine followed, and industrial production made the monohydrate widely available as a purified powder. Interest expanded in the late twentieth century when researchers began studying creatine supplementation and muscle physiology. Historical accounts sometimes differ on exact dates and attributions, but the broad sequence from tissue extracts to synthetic production is well documented.

Creatine-monohydrate at a glance

PropertyValueNotes
Chemical formula (monohydrate)C4H11N3O3Includes one water molecule per creatine unit.
Molecular weight149.15 g/molCalculated for the monohydrate; anhydrous creatine is 131.13 g/mol.
AppearanceWhite crystalline powderOdorless; particle size can vary by manufacturing.
CAS Registry Number6020-87-7Identifies creatine monohydrate; creatine base is 57-00-1.
Common synonymsCreatine hydrate; methylguanidoacetic acid monohydrateNaming varies by registry and supplier.

Chemical Identity and Background

In the body, creatine is synthesized from arginine, glycine, and methionine, mainly in the liver and kidneys, and is also obtained from foods such as meat and fish. About 95% of body creatine is stored in skeletal muscle, where a fraction is phosphorylated to phosphocreatine. Phosphocreatine serves as a rapid reserve of high-energy phosphate for short bursts of ATP regeneration. The monohydrate form supplies creatine after dissolution and absorption, but it is not itself the active phosphorylated species.

Creatine was first identified in skeletal muscle extracts in the nineteenth century, and its role in phosphagen energy buffering was clarified in the twentieth century. The monohydrate salt became widely studied after methods for inexpensive synthesis and crystallization were developed. Modern research examines its effects on muscle energetics, recovery, and cognitive performance under specific conditions. Findings vary with population, exercise protocol, baseline creatine status, and measurement method. Studies often compare supplementation with placebo during controlled training or testing schedules.

Related pages on this site

Purity, Stability, and Regulation

Solid creatine monohydrate is generally stable when kept cool and dry, but it can hydrolyze to creatinine over time. Moisture, heat, and acidic conditions accelerate this conversion, which reduces assay values and changes the material's properties. Creatinine is a cyclic dehydration product that is also a normal human metabolite, so its presence in a sample is not necessarily a health concern by itself. In quality testing, creatinine is monitored as a marker of degradation and purity.

Identity and purity are assessed with several complementary methods. High-performance liquid chromatography can separate creatine from creatinine and related impurities, often with ultraviolet detection. Nuclear magnetic resonance and infrared spectroscopy provide structural confirmation, while Karl Fischer titration measures water content. Elemental analysis and mass spectrometry may be used for additional confirmation, especially in research or forensic settings. No single method captures every quality attribute, so laboratories typically combine results and compare them against a specification.

Creatine Monohydrate Identity and Sources

Creatine monohydrate is a crystalline compound formed when one molecule of creatine binds with one molecule of water. Creatine itself is a nitrogen-containing organic acid involved in cellular energy transfer, particularly in muscle and nerve tissue. The monohydrate form is the most common solid form used in research and commercial products because it is relatively stable and easy to handle. Its molecular formula is C4H9N3O2·H2O, and its molar mass is about 149.15 grams per mole.

In the human body, creatine is synthesized mainly in the liver and kidneys from the amino acids glycine, arginine, and methionine. Dietary sources include meat, fish, and other animal tissues, which supply preformed creatine. Because plant foods contain little or no creatine, dietary intake varies widely among populations. The compound is stored largely in skeletal muscle, where it is converted to phosphocreatine and used to regenerate adenosine triphosphate during short bursts of activity.

Creatine monohydrate is one of several solid forms of creatine described in the literature. Other forms include anhydrous creatine, creatine hydrochloride, and creatine ethyl ester, each with different solubility and stability characteristics. The monohydrate is distinct from creatinine, a spontaneous breakdown compound that forms when creatine loses water and cyclizes. Commercial descriptions sometimes use synonyms such as methylguanidoacetic acid or N-(aminoiminomethyl)-N-methylglycine, which refer to the same base molecule. These names appear in chemical databases and product labels.

Notes from published material

In March 2021, Grimstone finalized a deal between the UK and Mubadala, allowing it to oversee investment of around £10 billion in the UK from the UAE. A senior research officer at Transparency International UK, Rose Whiffen said if a minister is working for a firm and meeting its shareholder several times while in office, it should be declared or assessed before approval. A unit of the company, Mubadala Capital, invested €50 million in the Novalpina Capital private equity fund of €1 billion, which bought the Israeli security company NSO Group in 2019. Reports revealed that the UAE targeted human rights activists, journalists, and Princess Haya using the Pegasus spyware, during the same time. Mubadala Capital got a seat on Novalpina's committee of largest investors. In 2021, Mubadala invested in wefox, a German digital insurance platform, through a $650 million funding round and led another $400 million round in 2022. In May 2022, Mubadala Investment Company signed a preliminary agreement with French utility Engie for the development of a digital platform to charge electric vehicles in the UAE and across the Middle East. The two companies would also explore areas related to sustainable mobility. In 2022, Mubadala sold the Anglo-Trade Bank, which it funded together with AGTB Holdings in 2018, to Gulf Islamic Investments. In April 2023 Mubadala, together with Stone Point Capital and other partners, acquired 20% of Truist Insurance Holdings for $1.95 billion.

=== Toxicity === Iron is also potentially toxic. Its ability to donate and accept electrons means that it can catalyze the conversion of hydrogen peroxide into free radicals. Free radicals can cause damage to a wide variety of cellular structures, and ultimately kill the cell. Iron bound to proteins or cofactors such as heme is safe. Also, there are virtually no truly free iron ions in the cell, since they readily form complexes with organic molecules. However, some of the intracellular iron is bound to low-affinity complexes, and is termed labile iron or "free" iron. Iron in such complexes can cause damage as described above. To prevent that kind of damage, all life forms that use iron bind the iron atoms to proteins. This binding allows cells to benefit from iron while also limiting its ability to do harm. Typical intracellular labile iron concentrations in bacteria are 10–20 micromolar, though they can be 10-fold higher in anaerobic environment, where free radicals and reactive oxygen species are scarcer. In mammalian cells, intracellular labile iron concentrations are typically smaller than 1 micromolar, less than 5 percent of total cellular iron.

Based on this, Johnson responded to Kennedy, concluding that much more was needed to reach a position of leadership, and recommending that the crewed Moon landing was far enough in the future that the US had a fighting chance to achieve it first. Kennedy ultimately decided to pursue what became the Apollo program, and on May 25 took the opportunity to ask for Congressional support in a Cold War speech titled "Special Message on Urgent National Needs". He justified the program in terms of its importance to national security, and its focus of the nation's energies on other scientific and social fields. He rallied popular support for the program in his "We choose to go to the Moon" speech, on September 12, 1962, before a large crowd at Rice University Stadium, in Houston, Texas, near the construction site of the new Lyndon B. Johnson Space Center facility. Khrushchev responded to Kennedy's challenge with silence, refusing to publicly confirm or deny the Soviets were pursuing a "Moon race". As later disclosed, the Soviet Union secretly pursued two competing crewed lunar programs. Soviet Decree 655–268, On Work on the Exploration of the Moon and Mastery of Space, issued in August 1964, directed Vladimir Chelomei to develop a Moon flyby program with a projected first flight by the end of 1966, and directed Korolev to develop the Moon landing program with a first flight by the end of 1967. In September 1965, Chelomei's flyby program was assigned to Korolev, who redesigned the cislunar mission to use his own Soyuz 7K-L1 spacecraft and Chelomei's Proton rocket.

Overall, GSK-3 appears to both promote and inhibit apoptosis, and this regulation varies depending on the specific molecular and cellular context. GSK-3 is also involved in nuclear transcriptional activator kappa B (NFκB) signaling pathway, Hedgehog signaling pathway, Notch signaling pathway, and epithelial-mesenchymal transition. Due to its importance across numerous cellular functions, GSK-3 activity is subject to tight regulation and is considered an "Ace" among kinases. The speed and efficacy of GSK-3 phosphorylation is regulated by several factors. Phosphorylation of certain GSK-3 residues can increase or decrease its ability to bind substrate. Phosphorylation at tyrosine-216 in GSK-3β or tyrosine-279 in GSK-3α enhances the enzymatic activity of GSK-3, while phosphorylation of autoinhibitory serine-9 in GSK-3β or serine-21 in GSK-3α significantly decreases active site availability (see figure). Further, GSK-3 is unusual among kinases in that it usually requires a "priming kinase" to first phosphorylate a substrate. A phosphorylated serine or threonine residue located four amino acids C-terminal to the target site of phosphorylation allows the substrate to bind a pocket of positive charge formed by arginine and lysine residues. Depending on the pathway in which it is being utilized, GSK-3 may be further regulated by cellular localization or the formation of protein complexes.

== Epidemiology == MSUD is a historically rare metabolic disorder with a worldwide incidence rate of about one in 185,000 live births. However, certain founder populations are much more prone to MSUD. For example, the Old Order Mennonites of Pennsylvania, produce as many as one in 200 live birth with MSUD. Maple syrup urine disease is classified as an autosomal recessive disorder and has a higher prevalence in populations that have higher consanguinity. Infants who are not treated for early onset MSUD experience a significant delay in development and usually die within a few months of birth. Younger children with late-onset MSUD may experience developmental delay also, depending on the enzyme activity of BKCD (branched-chain alpha-keto acid dehydrogenase). In children with periods of increased protein catabolism, there is an increased risk for metabolic decompensation. Early diagnosis can prevent morbidity in most cases as long as correct treatment is administered at presentation and periods of possible metabolic decompensation. MSUD occurs in all ethnic groups and the sex of the infant/child does not play a role in prevalence. NBS (newborn screening) programs incorporate MSUD screening in the United States, five provinces in Canada, Twenty-two European countries, eight Asian Pacific countries, and two Latin American countries.

Sources: en.wikipedia.org

Background from the literature

The OpenMS Proteomics Pipeline (TOPP) is a set of computational tools that can be chained together to tailor problem-specific analysis pipelines for HPLC-MS data. It transforms most of the OpenMS functionality into small command line tools that are the building blocks for more complex analysis pipelines. The functionality of the tools ranges from data preprocessing (file format conversion, baseline reduction, noise reduction, peak picking, map alignment,...) over quantitation (isotope-labeled and label-free) to identification (wrapper tools for Mascot, Sequest, InsPecT and OMSSA). TOPP is developed in the groups of Prof. Knut Reinert [1] at the Free University of Berlin and in the group of Prof. Kohlbacher [2] at the University of Tübingen. For more detailed information about the TOPP tools, see the TOPP documentation of the latest release and the TOPP publication in the references. The OpenMS Proteomics Pipeline is free software released under the 3-clause BSD license.

=== Analogues === Analogues of ETH-LAD include nor-LSD, LSD, PRO-LAD, IP-LAD, AL-LAD, FLUORETH-LAD, and CE-LAD, among others. 1P-ETH-LAD, a prodrug of ETH-LAD, has been developed and encountered as a novel designer drug.

GLaDOS (Genetic Lifeform and Disk Operating System) is a rampant artificial intelligence computer system that controls Aperture Laboratories, and is the primary antagonist for the Portal series. She is voiced by Ellen McLain. She awakens the player-character Chell in the first game, tasking her through the dangerous testing course, but Chell manages to escape and appears to destroy her, though later revealed to have had her personality stored within a black box. Within the second game, Wheatley accidentally reawakens GLaDOS, and eventually convinces Chell to initiate a core transfer to replace her with himself. GLaDOS, placed into a module powered by a potato battery, is forced to work with Chell to depose Wheatley from power before the Aperture facility is destroyed. While exploring the older sections of the facility with GLaDOS's potato battery form (known informally as "PotatOS" by fans), it is revealed that her consciousness is based, at least in part, on an uploaded version of Cave Johnson's assistant, Caroline. Caroline was unwilling to be uploaded to a computer, but was forced to do so by Cave. This potentially contributed to GLaDOS's homicidal tendencies, alongside the mental adjustments and tweaking performed by the scientists working on her. In the tie-in comic Portal 2: Lab Rat, it is revealed that the personality cores, such as Wheatley, were attached to GLaDOS in an attempt to manage and control her by acting as an artificial "conscience." Discussing the morality core, scientist Doug Rattmann quips, "You can always ignore your conscience."

His suicide and the deaths of two other former child actors would inspire the founding by former child actor Paul Petersen of the advocacy and support group A Minor Consideration in 1990. Jenő Ghyczy, 88, Hungarian Foreign Minister from 1943 to 1944

Sources: en.wikipedia.org

Further detail

Since thaumatin crystallizes very quickly and easily in the presence of tartrate ions, thaumatin-tartrate mixtures are frequently used as model systems to study protein crystallization. The solubility of thaumatin, its crystal habit, and mechanism of crystal formation are dependent upon the chirality of precipitant used. When crystallized with L- tartrate, thaumatin forms bipyramidal crystals and displays a solubility that increases with temperature; with D- and meso-tartrate, it forms stubby and prismatic crystals and displays a solubility that decreases with temperature. This suggests control of precipitant chirality may be an important factor in protein crystallization in general.

=== Homologues === Each domain of life (Eubacteria, Archaea, and Eukaryotes) have different release factors associated with the termination of translation. Eubacteria have multiple release factor to recognize stop codons whereas Eukaryotes (eRF1) and Archaea (aRF1) have only one protein to recognize all three stop codons. The structural and functional differences between Eubacteria release factors and Archean/Eukaryotic are believed to have evolved separately with a divergence point early on. The functional similarities between eRF1 and aRF1 has led to theories of a common ancestor where both proteins evolved from. However, very little has been studied about Archean release factors. In prokaryotes, the release factors are characterized in 2 classes. Class 1 release factors recognize stop codon, and class 2 release factors stimulate hydrolysis by GTPase activity. However, prokaryotes don't have a single protein to recognize all the stop codons. The stop codon UAG is decoded by Release Factor 1 (RF1) and UGA is decoded by Release Factor 2. The final stop codon UAA is decoded by both RF1 and RF2. In Eukaryotes, eRF1 recognizes all three stop codons. Although there is a distinct difference between prokaryotic codon recognition and Archean/Eukaryotic codon recognition, the functionality of the catalytic site is conserved throughout all domains. Each domain has the critical GGQ site to promote peptide hydrolysis.

Inductively coupled plasma (ICP) sources are used primarily for cation analysis of a wide array of sample types. In this source, a plasma that is electrically neutral overall, but that has had a substantial fraction of its atoms ionized by high temperature, is used to atomize introduced sample molecules and to further strip the outer electrons from those atoms. The plasma is usually generated from argon gas, since the first ionization energy of argon atoms is higher than the first of any other elements except He, F and Ne, but lower than the second ionization energy of all except the most electropositive metals. The heating is achieved by a radio-frequency current passed through a coil surrounding the plasma.

Sources: en.wikipedia.org

Frequently asked questions

What is the difference between creatine and creatine monohydrate?

Creatine is the base compound, while creatine monohydrate includes one water molecule per creatine molecule in its crystal structure. The monohydrate form is common in supplements and analytical standards. The body uses creatine itself after the water is removed or dissociated.

Is creatine monohydrate found naturally in food?

Yes. Meat, fish, and other animal tissues contain creatine. Cooking can convert some creatine to creatinine, which has no role in phosphocreatine energy buffering. Plant foods contain little or no creatine.

Does creatine monohydrate differ from creatinine?

Creatinine is a cyclic breakdown product formed from creatine and phosphocreatine. It is filtered by the kidneys and commonly measured in blood and urine as a marker of renal function. Creatine monohydrate is a supplement ingredient and research chemical, not the same molecule.

What is creatine monohydrate?

It is a crystalline form of creatine that contains one water molecule per creatine molecule. The compound occurs naturally in muscle tissue and is also produced synthetically for research and consumer products. The monohydrate label describes the solid's hydration state.

Network